Boston Scientific (BSX) Guidance Cut Due to Cyberattack Impact
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowBoston Scientific Corporation (NYSE: BSX) experienced a 2.3% decline in trading on September 8, 2026, following a cyberattack on August 25 that disrupted manufacturing and shipping. The company announced it is unlikely to meet its previously provided guidance for third-quarter and full-year net sales and adjusted earnings per share for 2026. While operations have resumed, the cyberattack’s effects are anticipated to impact the company's financial performance. This situation highlights operational vulnerabilities that investors might not have fully considered, creating caution regarding future earnings expectations.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Boston Scientific Corporation (BSX)
Boston Scientific makes medical devices for cardiology and other specialties.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BSX news
- Boston Scientific (BSX) Shares Fall 3.5% Due to Cyberattack
- Boston Scientific stock down 0.4% on market changes
- Boston Scientific (BSX) reports $5.4B Q2 revenue with 7.5% growth
- Boston Scientific (BSX) Price Target Cut to $64 by Truist
- Boston Scientific (BSX) Price Target Cut by Jefferies on Growth Outlook
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
